Member Info for smeeagainbruce

GSK were the first to get FDA approval for RSV closely followed by Pfizer ( ABRYSVO ). AZN / Sanofi have a treatment to protect babies from the virus, multiple shots at the market. GSK vaccine is for patients over 60 years of age. Time will tell who gets what share of the market, hence the cool response to the news imo. DYOR

TerryMC1 and RonnieH contribute doom and gloom on numerous BB's, 407 posts in the last 30 days between them. Check out their posting history, pathetic delusional traders.

The vultures may arrive sooner than you think LL. The main stream media can be engaged on "The Quality of Life Improvement". That is an angle with the data we have can be talked about. So when phase 1a is complete there is an opportunity to inform the media chemotherapy with significant reduction in side effects achieved.

https://www.youtube.com/watch?v=DlHRRmycxTY ( 1.01.08 in ) AS reveals main stream media involvement possible.

Forget the LFD stitch up, how many know Avct produced Affimers which were POTENT inhibitors of the virus entry into human cells. Timing once again played its part in not developing a therapy for covid. The Centre for Virus Research at Glasgow University reported given the excellent performance of these novel reagents there should be considerable interest from potential partners in developing them as a Therapy for covid.

No interest was forthcoming because vaccines were being developed, this option can now be acted upon for the next virus of concern. The platform now proven can deliver a therapy, an alternative to vaccines.

Put a value on a Company who can produce Affimers in weeks capable of inhibiting a virus entering human cells. Mechanical Engineering is my back ground however this head in the sand view is frankly bewildering.

Affimers imo outperform Antibodies and on this assumption the sky is the limit. So many avenues to go down, mind blowing.

Communication was raised and AS said they were getting to a point where we can engage with that sort of media (Main stream ). Quality of life improvement, that's an angle we can talk about with the data available. Chemotherapy with significantly reduced side effects would be a massive headline.

A statement was made, pre|CISION gets Dox through the stroma and into the cancer cells at the same time. The stroma was described as a barricade surrounding the cancer cells. This is where ADC'S can be improved imo, antibodies find it difficult to get passed the barricade.

How do we know it's efficacious in non receptive patients, not all the patients slotted into this category.

https://www.youtube.com/watch?v=226XiA84i7w (6 mins 5 sec in )

Those patients we are taking into phase 1a don't necessarily and the vast majority don't have tumours that are treatable with Doxorubicin so we wouldn't expect efficacy with these patients.

Therefore some patients did have tumours which responded to Dox, still a fantastic result and one you would expect.

The sites in the US repeat the findings in today's RNS. They are contributing to the dose escalation phase and the probability someone will be benefiting from the treatment is high imo. If any of the patients recruited had a cancer which responded well to Dox then the possibility of repeating today's news is a distinct possibility.

Keeping a lid on this SP is not going to work for very much longer.

Triton bought his company because it was attracted to the differentiation Clingen created through a combination of services across the Pharmaceutical product lifestyle, from phase 11 clinical trials to commercialisation of both licensed and unlicensed medicines. Their words not mine, however it demonstrates he thinks this is a good opportunity joining Avct. What I wonder could he help take from phase 11 clinical trials to the market place

He acquired the global rights for Proleukin after Novartis accepted a $210m fee in exchange for the asset. Has form with the big boys.

You make money with Aptamers, trading maybe if you bought at 10p. Why the second RNS stating the group is not aware of any material commercial or operational reason for the significant increase in its share price.

So all the covid tests made in collaboration with Mologic are not flying of the shelves.

https://bionow.co.uk/news/b6051da7f540ee/aptamer-group-and-mologic-enter-commercial-partnership-to-develop-aptamer-based-sars-cov-2-rapid-antigen-test

How about the deal with AstraZeneca, maybe this is about to blow .

Then there's the deal with Deepverge supplying millions of pounds worth of Optimers, no nothing on that front.

Where is the evidence Aptamer group are making money with their Optimers.

Aim at its best, certainly not profits from sales. Criminal.

Delays in LFD: PD using artificial samples, test not validated, clinical trials transferred to Spanish Hospital. Mologic designed the LFD architecture after Cytiva dropped. Mologic introduced an Antibody to the mix making TT difficult. All this contributed to a delay of almost a year. Antibody failed detecting Omicron reducing sensitivity and the test although up to the standard of approved tests removed from the market.

Where did Avct fail in this process, answers on the back of a postage stamp. PD, Mologic and a duff mAB took all the honours in this fiasco. Read the RNS ref the tests withdrawal, it worked to the standard achieved by the approved tests.

The rest is a fictional representation of the facts.

This bung crap is nonsense, Innova got in early doors because they could provide over 12,000 kits for a test in Liverpool quickly. They then shot themselves in the foot cheating the FDA, along came the rest of the Chinese tests by the millions. Ever wondered why they were first out of the gates with their LFT's beating Roche and Co to the big bucks in the UK.

Avct produced the Affimer reagent, the rest made an ar.e of it.

Coris products ; https://pdf.medicalexpo.com/pdf/coris-bioconcept/resist-bc/68113-245359.html

Covers a wide range of tests with the potential for the Affimer technology to improve or generate new products.

Interestingly Avct will halt the redevelopment of AffiDX LFD and market the Coris test. Obviously they have produced a high quality test and Avct feel its performance is up to their own high standards.

Before the whingers bombard the above statement with it didn't work crap provide the evidence too prove your statement. If you look at the S&S results of the Coris covid LFT you will observe they are compared to RT-PCR result and not a CT value. Based on the fact most PCR tests cut off point was Ct 40 the results provided prove the quality of the test imo.

So why when this product was placed on the market in 2020 did it bomb. Was it because the CEO had no business nous or maybe a total numpty not to earn the enormous profits made by the crap approved at Porton Down. In the end fortunes were made producing not the best tests, the high volume mediocre tests churned out initially by a Chinese company who knew a Pandemic was on its way tests.

Whingers homework, provide the third party evidence all the approved LFT's detected the Omicron variant without loss in sensitivity. Should be a fairly easy task, supposedly they all worked , no opinions please stick to the facts. Superb acquisition, that's an opinion.

Https://www.clinicaltrials.gov/ct2/show/NCT04969835?term=NCT04969835&draw=2&rank=1

Safety and Tolerability aspect ongoing and proving pre|CISION works or am I missing something here. The next step is to prove AVA 6000 increases the Doxorubicin therapeutic index. Results would suggest it should however the Regulators need proof and the market wants proof.

What they do not see is pre|CISION is the golden nugget, not what it is delivering imo. Unless I have totally misinterpreted the situation pre|CISION opens the door to a multitude of applications. Targeting a therapy is the way ahead and Avct imo has struck gold. The SP and where it sits is irrelevant, you either have your head in the sand or basic facts prove the technology works.

Almost a 50% increase in SP over the last month or so, Lantheus deal secured their financial future and the only company to have a licensing deal with Avct for pre/CISION (CanSEEK). With pre/CISION providing what looks like a huge breakthrough in targeted therapies they are imo about to become a leading player in this multi billion $ market.

Royalties for Avct and the start of numerous licensing deals as the big boys realise pre/CISION can increase their drugs therapeutic value with reduce side effects. AVA6000 / 3996 are the trailers with the big picture about to be released.

Add it up whatever way choose, the end result remains the same, a treatment with side effects.
https://www.mayoclinic.org/drugs-supplements/nivolumab-intravenous-route/side-effects/drg-20127723?p=1
Now, find a way to reduce /remove the side effects and bingo, they could be on to a winner. Anybody know of such a process !!!

Great find gmcc, highlights the enormous potential of pre/CISION, the prodrugs produced so far are but a few in a mind blowing new generation of targeted drugs imo. Avct / Point Biopharma being the beneficiary of targeting FAP, a good piece of business licensing pre/CISION to PB by Avct. Money for nothing from the Radiopharmaceutical business, pre/CISION is the gold mine. The rest is the golden nuggets it will produce. Happy days.
The inventor is about to start the next gold rush imo.

Pre-Clinical Data & Next Steps, a heading on page 92 of the document attached.
https://www.sec.gov/Archives/edgar/data/1811764/000110465921098307/tm2123357-1_s1.htm
Clear intension to target PSMA and Prostate cancer and therefore a CanSEEK technology target. They are certainly aware of the eagerly awaited dated and imo have only one possible way forward. Avct / pre/CISION will target Prostate cancer with reduced side effects.

Thorn I do not deal in assumptions only pure fact, you are assuming the Affimer v Antibody comment has no factual evidence.
In my possession I hold two UK approved LFT's , Orient Gene and Flowflex and below is a link to comparative sensitivity evaluation for 122 CE marked LFT's.
https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.44.2100441
You will observe the two tests above have a Sensitivity of 87% / 4.3% respectively evaluated on a viral load of ( Ct >25 - < 30 )
If you care to do some research yourself you will see AffiDX LFD produced a higher sensitivity in this viral load range, fact.
Remember all the tests listed were evaluated pre-Omicron, what assumption can be made on how Omicron reduced their Sensitivity even more.
Interestingly another UK approved LFT Surescreen has a Sensitivity at the above viral load of 0%. A perfect example of how their Antibody performed against that " it didn't work" Affimer version.

The fact Astrea Bioseparations ditched Antibodies in favour of Affimers for purification purposes is evidence enough to challenge your assumption remark.
Please feel free to turn the facts produced into assumptions, look forward to hearing how your research is going .

The forgotten fact is Affimers are a superior alternative to Antibodies, a fact twisted by an incompetent validation process and the necessity to find an alternative, quick testing programme. The Innova fiasco led to an influx of mediocre LFD's being approved for public use. The fact remains Affimers outperformed Antibodies in the LFD saga, the third party clinical evaluations of all the approved tests confirms this fact.
Now we have Astrea Bioseparations a licensee of the Affimer platform being bought by Biotage who declared strategically the acquisition extends our company into higher growth, strengthens our financial profile and provides higher gross margins. In addition the acquisition brings a rich near term pipeline of a new product launches.
KKR a Global Investment firm arranged the merger (m/c $48 billion ) because they owned AB through their Life Science Tools Platform company Gamma Sciences.
KKR received a 17 % holding in Biotage and became their largest shareholder. All this based on Affimers being a superior alternative to Antibodies. Eventually the penny will drop, so far the news of the acquisition has fallen on fallow ground.

https://www.cambridgeindependent.co.uk/business/biotage-ab-acquires-astrea-bioseparations-for-235m-9301621/
AB agreement with Avct paying dividends, strategically the acquisition extends Biotage's chromatography franchise into the higher -growth and larger bioprocessing segment, while also increasing exposure to biologics and advanced therapeutic customers. Another success used in a field of use where Affimer reagents perform extremely well outside the main business focus.

The top man from America Dr Tap has no alternative for Doxorubicin and he is going home to accelerate the opportunity to find one asap. He wants new therapies to the patients quicker, 20 years of Dox and failed trials using a combination of drugs has wet his appetite imo.
The CEO/ Avct want to benefit cancer patients and his closing statement must have rocked the big Pharma's to their foundations. Cheaper drugs so many more patients can afford treatment, how they will react to a company who can reduce their profits has to be seen.. The pre/CISION Platform can deliver a multitude of cheaper therapies quickly.